On a relative basis, the stock has outperformed the S&P 500 by 7.88% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.5% in the last 1 week, and is up 12.6% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 7.04% and the 50-Day Moving Average is 9.09%.
Abbott Laboratories (NYSE:ABT): The stock opened at $42.40 on Friday but the bulls could not build on the opening and the stock topped out at $42.53 for the day. The stock traded down to $42.03 during the day, due to lack of any buying support eventually closed down at $42.10 with a loss of -0.43% for the day. The stock had closed at $42.28 on the previous day. The total traded volume was 7,693,538 shares.
The company Insiders own 0.26% of Abbott Laboratories shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.81% . Institutional Investors own 70.06% of Abbott Laboratories shares. In a related news, The Securities and Exchange Commission has divulged that Allen Hubert L, Officer (Executive Vice President) of ABBOTT LABORATORIES, had unloaded 3,400 shares at an average price of $37.14 in a transaction dated on June 28, 2016. The total value of the transaction was worth $126,276.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.